Gene therapy: its contributions to liver and kidney diseases
Mazzolini, G.; Ruiz, J.; Qian, C.; Prieto, J.
Nefrologia Publicacion Oficial de la Sociedad Espanola Nefrologia 21(Suppl 1): 17-23
2001
ISSN/ISBN: 0211-6995 PMID: 11382095 Document Number: 527610
Document emailed within 1 workday
Related Documents
Sangro, B.; Ruiz, J.; Qian, C.; Prieto, J. 2000: Gene therapy for liver diseases Gastroenterologia y Hepatologia 23(8): 394-402Vereskova, S.A. 1989: The conservative therapy of kidney diseases at the chronic kidney failure stage in children Fel'dsher i Akusherka 54(4): 37-40
Briedigkeit, H.; Precht, K. 1983: Antibiotic therapy in kidney diseases with reduced kidney function Zeitschrift für Arztliche Fortbildung 77(3): 95-99
Ballermann, B.J. 2000: Gene therapy in the vasculature and the kidney Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 20(Suppl 2): 19-24
Narita, I.; Gejyo, F. 2004: Gene polymorphisms of renin-angiotensin system in patients with kidney diseases Nihon Rinsho. Japanese Journal of Clinical Medicine 62(10): 1811-1815
Tareeva, I.E.; Nikolaev, A.Iu. 1980: Kidney lesion in liver diseases Klinicheskaia Meditsina 58(5): 6-13
Shulutko, B.I. 1972: Changes in the liver in chronic kidney diseases Terapevticheskii Arkhiv 44(2): 59-61
Ureña, P. 2008: Contributions of the software La Clé Concerto in the implementation of the NKF-K/DOQI (National Kidney Foundation-Kidney/Dialysis Outcomes Quality Initiative) recommendations for the control of mineral and bone metabolism disorders in the patient with chronic renal failure Nephrologie and Therapeutique 4 Spec no 1: 9
Hogan, M.C.; Torres, V.E. 2008: What the similarities of specific polycystic liver and kidney diseases can teach us about both Nephrology News and Issues 22(9): 29-31
Kolenda, K.D.; Jost, S.; Kokenge, F. 1981: Digoxin or digitoxin? Glycoside choice in old age and in kidney and liver diseases Therapie der Gegenwart 120(1): 21-39
Trushina, E.N. 1983: Kidney changes in acute and chronic liver diseases and in alimentary damage Voprosy Pitaniia 4: 16-22
Held, E. 1988: What is established in the therapy of kidney diseases? Der Urologe. Ausg. a 27(6): 313-320
Asano, S. 1974: Kidney diseases and diet therapy Nihon Jinzo Gakkai Shi 16(5): 488-493
Martinet, O.; Reis, E.D.; Gillet, M. 1999: Gene therapy and liver metastases Schweizerische Medizinische Wochenschrift 129(34): 1187-1195
Laky, D.; Cândea, V.; Popa, A.; Tintoiu, I.; Cândea, B.T.; Porumb, M.; Socolovschi, S. 1989: Contributions to the biology of the hypoxic liver. Note I. Histological and electronmicroscopical aspects of the liver in chronic congestive heart failure Morphologie et Embryologie 35(4): 269-273
Leuschner, U. 1998: Cholestatic liver diseases--diagnosis and therapy. 3: Therapy of primary biliary cirrhosis Fortschritte der Medizin 116(1-2): 37-39
Attramadal, H.; Berg, K. 2001: Gene therapy in cardiovascular diseases Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 121(4): 489-491
Viet Tran, H.; Schorderet, D.F.; Kostic, C.; Munier, F.L.; Arsenijevic, Y. 2009: Gene therapy for hereditary eye diseases: where are we? Revue Medicale Suisse 5(186): 118-123
Havlík, R. 2000: Gene therapy strategies for liver tumours Acta Universitatis Palackianae Olomucensis Facultatis Medicae 143: 83
Ohashi, T. 2010: Gene therapy for lysosomal storage diseases Nihon Rinsho. Japanese Journal of Clinical Medicine 68(Suppl 8): 665-669